Medtronic Lifts Outlook as Revenue Jumps

Medtronic(NYSE:MDT) reported first quarter fiscal 2026 results on August 19, 2025, delivering 4.8% year-over-year organic revenue growth and adjusted earnings per share (EPS) of $1.26, which beat the midpoint of prior guidance by $0.03 (adjusted). Management raised full-year fiscal 2026 EPS guidance to $5.60--$5.66, citing accelerating growth drivers, EPS leverage from operational improvements, and the upcoming Diabetes separation. The call unveiled major operational milestones in pulsed field ablation (PFA), highlighted transformative progress in Renal Denervation, and detailed newly announced board and governance changes in partnership with Elliott Management, all of which shape the company's long-term investment trajectory.The Cardiac Ablation Solutions (CAS) business posted nearly 50% year-over-year organic revenue growth, including low 70s% growth in both the U.S. and Japan and low 30s% growth in international markets, with the $11 billion addressable PFA market now expanding above 25% per year. Recent product momentum from the Affera mapping system and Sphere-9 focal catheter, alongside upcoming pivotal trials for the next-gen Sphere-360 single-shot catheter expected to start in CY2025, positions Medtronic to expand market share and capitalize on high sequential and annual organic revenue growth trends.Medtronic's rapid expansion in PFA, supported by strong product adoption and a robust innovation pipeline, is driving significant share gains in a high-growth market segment.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool